Drugs / ALX2004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07085091 | Aug 2025 → Jun 2027 expected | colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | ALX Oncology Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALX2004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085091 ↗ |
| Route | Intravenous | “Drug: ALX2004 IV Infusion” NCT07085091 ↗ |
| Target | EGFR | “ALX2004 is a novel ADC targeting EGFR.” NCT07085091 ↗ |